<DOC>
	<DOC>NCT03103334</DOC>
	<brief_summary>The objective is to determine whether the test product, Methotrexate 40 mg/mL solution for injection administered subcutaneously by the prefilled and needle-free delivery system Zeneo®, and the reference product, Methotrexate Biodim® 25 mg/mL, solution for injection administered subcutaneously by a conventional syringe with needle are bioequivalent.</brief_summary>
	<brief_title>A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.</brief_title>
	<detailed_description />
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Healthy subjects BMI between 18.5 and 30 kg/m2 Body mass &gt; 60 kg Nontobacco user Written consent given for participation in the study Evidence of clinically relevant oral, cardiovascular, hematologic, gastrointestinal, hepatic, renal, endocrine, pulmonary, neurologic, psychiatric or skin disorder Heavy alcohol consumption and regular exposure to drug of abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>